Consistent with the development of a CD8+ T cell-mediated memory response, splenic CD8+ cells from mice treated with atovaquone plus aPD-L1 experiencing durable tumour eradication showed increased levels of T cell activation markers (CD44, PD-1) when challenged ex vivo with CT26 cells (Fig. 3D, E). This evidence concerns the gene CD8A and neoplasm.